Ligand Pharmaceuticals Inc - Class B
Research Ligand Pharmaceuticals Inc - Class B (LGND) on Bullrun: valuation model: 35.2% overvalued, market cap USD 6.29B, P/E 42.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLGND
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal35.2% overvalued
- Market capUSD 6.29B
- P/E42.6
- Financial periodFY2025
- RevenueUSD 268.09M
- Revenue growth60.4%
- Net incomeUSD 124.45M
- Free cash flowUSD 48.91M
Valuation Snapshot
Bullrun's latest valuation model marks Ligand Pharmaceuticals Inc - Class B as 35.2% overvalued; latest market cap is USD 6.29B; P/E is 42.6.
About Ligand Pharmaceuticals Inc - Class B
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Frequently asked questions
Is Ligand Pharmaceuticals Inc - Class B overvalued or undervalued?
Bullrun's valuation model currently marks Ligand Pharmaceuticals Inc - Class B as 35.2% overvalued.
What is Ligand Pharmaceuticals Inc - Class B's market cap?
Ligand Pharmaceuticals Inc - Class B's market capitalization is USD 6.29B.
What is Ligand Pharmaceuticals Inc - Class B's P/E ratio?
Ligand Pharmaceuticals Inc - Class B's price-to-earnings (P/E) ratio is 42.6.
What does Ligand Pharmaceuticals Inc - Class B do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma;